Knowledge Base:  
You are here: Knowledge Base >
K2 Facts Drug Detection & Side Effects
Last Updated: 11/27/2010
K2 is a synthetic form of marijuana. Some people compare the effects of K2 to marijuana. Right now the drug is legal in certain sectors of the United States, but some states are trying to pass bills to ban the drug.

On November 24th 2010 in the Federal Register, the DEA issued a notice of intent to temporarily place five synthetic cannabinoids into the Controlled Substances Act (CSA) pursuant to the temporary scheduling provisions under 21 U.S.C. 811(h) of the CSA.

As a warning to parents, US citizens and thousands of drug detection agencies across the United States K-2 is sold in head shops as incense although people do, more often than not, smoke it. It is currently not detectable on drug tests, however, JWH-018 chemical within K2 is detectable within certain labs (see more below).

JWH-018 produces effects very similar to cannabis but is considerably more potent than similar amounts of cannabis. The drug does not show up in drug test results for cannabis, but its metabolites can be detected in human urine by GC-MS-screening and LC-MS/MS.[18][19][20]


Recent articles have been cropping up as legislatures continues to ban the chemicals in K2.

From Wikipedia, the free encyclopedia

K2 is a herbal smoking blend made of herbs and spices sprayed with synthetic cannabinoids (notably JWH-018, chemically similar to THC), which mimic the effects of Marijuana. It is produced in China. It is rolled into a cigarette and smoked in a manner similar to marijuana.[1]

It is a product similar to Spice.[2] K2 comes in many varieties with names such as Blonde, Summit, Pink, Blue, Standard, and Citron[3] No studies have been done on its effects on humans.[4]

It is legal and readily available throughout most of the United States. Its use has sparked alarm in Kansas and Missouri, which are contemplating legal bans.[5] but has not raised such objection in Michigan[6]. The US Army has banned soldiers' use.[7

source

State health officials adopt emergency rule banning K2

By John Lyon
Arkansas News Bureau

LITTLE ROCK — The state Board of Health adopted an emergency rule today to ban the sale of synthetic marijuana, or K2, though one member complained that the board was responding to political pressure rather than a true emergency.

Gov. Mike Beebe signed the rule shortly afterward, making it effective immediately.
The rule makes the sale of K2 — also called Spice and several other names — a misdemeanor punishable with a fine of up to $500 and up to one month in jail. It also includes a civil penalty of up to $1,000.
-------------------------------
The K2 Herb is now banned in Missouri, the 5th state in the United States to put a ban on the use of the marijuana-like herb. Kansas and Kentucky have banned the sale and possession of its active chemicals.

The Arkansas Board of Health has approved an emergency order to ban K2 on July 2, 2010. Alabama has also banned the K2 herb. http://dailypostal.com/2010/07/10/k2-herb-banned-in-some-states/

Georgia, Mississippi, Tennessee, Louisiana, Michigan, and Illinois are also seeking to ban the substance.
--------------------------------
The following resourceful info derives from Paul Cary | Spice, K2, and the Problem of Synthetic Cannabinoids see entire PDF

Due to the nature of this subject matter and the limited amount of scientific information on synthetic cannabinoids, much of the source material used in this publication was obtained from news organizations, relevant web sites and personal communications with government officials, researchers, laboratory directors and actual synthetic cannabinoids users. Other source materials included the following:
1. Analytical Profile of Two Synthetic Cannabinoids – JWH-018 ND JWH-073, Malinda Combs and Jeremiah A. Morris, in Journal Clandestine Laboratory Investigating Chemists Association, Volume 20, Number 2, April 2010.
2. The Synthetic Cannabinoid HU210 Induces Spatial Memory Deficits and Suppresses Hippocampal Firing Rate in Rats, RG Pertwee, RE Hampson, G Riedel - in British Journal Pharmacology, Volume 151(5): 688–700, July 2009.
3. Spice - Request for Information, DEA - Office of Diversion Control, National Forensic Laboratory Information System, Year 2008 Annual Report.
4. DEA, Drugs and Chemicals of Concern, July 2009.
5. Spice Drugs as a New Trend: Mode of Action, Identification and Legislation, I. Vardakou, C. Pistos, and Ch. Spiliopoulou, in Toxicology Letter, in Press.
6. Understanding the Spice Phenomenon, A Wohlfarth, W Weinmann in
Bioanalysis, May 2010, Vol. 2, No. 5, Pages 965-979.
7. Withdrawal Phenomena and Dependence Syndrome After the Consumption of "Spice Gold", Ulrich S. Zimmermann, Patricia R. Winkelmann, Max Pilhatsch, Josef A Nees, Rainer Spanagel, Katja Schulz in Deutsches Ärzteblatt InternationalDtsch Arztebl Int 2009; 106(27):464–67.
8. Identification of a Cannabinoid Analog as a New Type of Designer Drug in a
Herbal Product, Nahoko Uchiyama, Ruri Kikura-Hanajiri, Nobuo Kawahara, Yuji Haishima and Yukihiro Goda in Chemical & Pharmaceutical Bulletin
Vol. 57 (2009), No. 4 p. 439.
9. Spice and Other Herbal Blends: Harmless Incense or Cannabinoid Designer Drugs?, Auwärter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M., Ferreiros, N., in Journal of Mass Spectrometry, Volume 44, 832–837, 2009.
10. Design, Synthesis, and Pharmacology of Cannabimimetic Indoles, Huffman, J.W., Dai, D., Martin, B.R., Compton, D.R., in Biomedical Chemistry, Volume 4, 563–566, 1994.
11. Consideration of the Major Cannabinoid Agonists. in Advisory Council on the Misuse of Drugs (ACMD), July 2009.
12. The Growing Buzz on 'Spice' -- the Marijuana Alternative, by Michael W. Savage, Washington Post Staff Writer, Saturday, July 10, 2010.
13. Spice: A Never Ending Story?, Rainer Lindigkeit, Anja Boehme, Ina Eiserloh, Maike Luebbecke, Marion Wiggermann, Ludger Ernst, Till Beuerle, in Forensic Science International Volume 191, (2009) 58–63.
14. Fact Sheet - A Selection of Internet-Based Information - JWH-018, Nathalie Deprez and Marc Roelands, Scientific Institute of Public Health, Brussels, November 2008.
 
 


Was this article helpful?

Comments: